NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Inovio Pharmaceuticals, Inc. (INO) Stock Analysis

Inovio Pharmaceuticals, Inc. (INO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

INO

$1.43

+$0.07 (+5.15%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INO with… →

INO Key Statistics

As of Sep 4, 2026
Trading
Open
$1.35
Previous Close
$1.36
Day's Range
1.35–1.43
52-Week Range
0.56–2.98
Volume
2.89M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.63
Valuation
Market Cap
$147.86M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.08
Financials (FY)
Revenue (FY)
$65.34K−69.99%
Net Income (FY)
−$84.95M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.40M
1-Year Return
−48.00%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
3.46M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

INO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.82%
2025−4.92%
2024−70.10%
2023−67.31%
2022−68.74%
2021−43.62%
2020+168.18%
2019−17.50%
2018−3.15%
2017−40.49%
2016 (partial year)−25.78%

As of September 4, 2026.

INO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$65.34K−$84.95M−130000.0%
2024$217.76K−$107.25M−49254.3%
2023$832.01K−$135.12M−16239.9%
2022$10.26M−$279.82M−2726.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$65.34K—−$86.82M−$84.95M−130000.0%
2024$217.76K—−$112.40M−$107.25M−49254.3%
2023$832.01K—−$133.43M−$135.12M−16239.9%
2022$10.26M—−$267.57M−$279.82M−2726.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INO Valuation vs Biotechnology Median

Median of 656 stocks
MetricINOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Inovio Pharmaceuticals, Inc. (INO) is capitalised at $147.86M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 112.

The most recent close on file for INO is $1.43, dated September 4, 2026. That is +$0.07 (+5.15%) against the previous close. Over the past 52 weeks the price has ranged from $0.56 to $2.98. The latest close sits 155.36% above that 52-week low.

Financial Health

In fiscal 2025, Inovio Pharmaceuticals, Inc. reported revenue of $65.34K. Against the prior fiscal year total of $217.76K, that is a change of −69.99%. The same year closed with a net loss of $84.95M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.08.

Across the 4 fiscal years on file, revenue moves from $10.26M in 2022 to $65.34K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.63. Daily returns over the trailing 10 years annualize to a volatility of 94.52%. Over the trailing twelve months the price has returned −48.00%. Across 10 years the annualized return works out at −35.17%.

Growth & Income

No dividend is on file for INO.

Across the complete calendar years on file, 2020 returned +168.18% and 2024 returned −70.10%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the price is −17.82%.

Peer Comparison

Inovio Pharmaceuticals, Inc. (INO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Inovio Pharmaceuticals, Inc. INO $147.86M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Inovio Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Visit website →